Author: Customer Service

BEIJING, March 15, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first healthy volunteer has been dosed in a clinical trial of ICP-538, a VAV1-directed molecular glue degrader (MGD), in China. This is the first VAV1 degrader approved to enter clinical trials in China and the second globally. ICP-538 is a novel, potent, highly selective, orally administered molecular glue degrader targeting VAV1, a key protein downstream of T-cell and B-cell receptors. ICP-538 induces rapid and efficient degradation of VAV1 protein in a dose-dependent manner by selectively mediating the formation of a ternary complex between the CRBN E3 ubiquitin ligase and the VAV1 protein. ICP-538 will be developed for...

Perth, Western Australia, March 16, 2026 (GLOBE NEWSWIRE) — PERSEUS ANNOUNCES SALE OF GROUP INTEREST IN MEYAS SAND PROJECT IN SUDAN HIGHLIGHTSPerseus has signed a Share Purchase Agreement (SPA) to sell its 70% group interest in the Meyas Sand Project (MSGP) located in Sudan to Hong Kong Matrix Golden Fortune Mining Limited (Buyer), a wholly owned subsidiary of Matrix Resources (Zhejiang) Co., Ltd. (together with its subsidiaries, the “Matrix Group”), for a cash consideration of US$260M. Purchase price comprises a US$10M deposit received on signing of the SPA and US$250M payable on completion of the transaction which is to occur on April 22, 2026. Proceeds will further strengthen Perseus superior balance sheet along with consideration of additional capital returns to shareholders.Perth, Western Australia/ March 16, 2026/...

MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®1, Floretyrosine F 18 or 18F-FET), an investigational PET2 imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients. Telix has resubmitted the NDA with the additional data requested by the FDA. The Company believes, based on the Type A meeting and ongoing consultation with the FDA, that the additional data and statistical analysis, along with the primary data set provided in the original submission, appropriately addresses the Complete Response Letter3. Given...

The Annual General Meeting of Iceland Seafood International hf will be held on Tuesday 24 March 2026 at 4pm at Hilton Reykjavík Nordica, Suðurlandsbraut 2, 108 Reykjavik, Iceland.  The meeting will be in Icelandic. Enclosed is the final agenda for the Annual General Meeting 2026 and final proposals. No changes have been made neither to the proposals nor the agenda since the meeting was convened. Information and documents for the Annual General Meeting can be found on the company’s website: Annual General Meeting (icelandseafood.com)AttachmentsISI_AGM_Notice to convene the AGM 2026ISI_AGM_Board Proposals 2026

New data shows positive real-world impact of the world’s first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes Eversense 365 delivered comparable adherence and outcomes between the first and second six-month period, indicating high accuracy and performance from a single sensor across an entire year GERMANTOWN, Md., March 14, 2026 (GLOBE NEWSWIRE) — Senseonics, a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announces new data from a real-world evidence study which demonstrates the sustained performance and positive impact of Eversense 365 across the full one-year period. These findings were presented during an oral presentation...

SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Juan Pablo Frías, MD, delivered an oral presentation at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (“ATTD”) in Barcelona on March 14, 2026 highlighting positive 52-week follow-up results from the Company’s Phase II COVALENT-111 study evaluating the efficacy, safety, and tolerability of icovamenib in patients with type 2 diabetes (“T2D”). “We are encouraged by the durability of icovamenib’s effect observed nine months post-dosing at Week 52,” said Mick Hitchcock, Ph.D., Interim CEO and Board Member of Biomea Fusion. “We believe that we now have in hand initial evidence of durable efficacy,...

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – VANCOUVER, BC, March 13, 2026 (GLOBE NEWSWIRE) — Digital Asset Technologies Inc. (CSE: DATT) (OTCPK: DGTEF) (FSE: 988) (“DATT” or the “Company”), a technology focused investment issuer, announces that it has entered into a settlement agreement (the “Agreement”) with its former auditor (the “Auditor”) for settlement and termination of a Notice of Civil Claim filed by the Auditor in the Supreme Court of British Columbia (the “Claim”). Pursuant to the Agreement, the Company will pay the Auditor $65,000 in cash, payable in five equal instalments of $13,000 each, and will issue 1,917,967 common shares of the Company (the “Settlement Shares”) at a deemed price of $0.02 per Settlement Share, as approved by the Canadian Securities Exchange (the...

Board of Directors will review letter to verify compliance with bylaws Stockholders are not required to take any action at this time LOUISVILLE, CO, March 13, 2026 (GLOBE NEWSWIRE) — CEA Industries Inc. (Nasdaq: BNC) (“BNC” or the “Company”) has confirmed receipt of a letter from YZILabs Management Ltd. (“YZi Labs”) requesting that the Company’s Board of Directors (the “Board”) set a record date in connection with YZi Labs’ consent solicitation (the “Request Letter”). The Request Letter is a required step in YZi Labs’ consent solicitation process to add up to seven directors to the Board. Because the current Board has only six Directors, this would effectively transfer control of the Board to YZi Labs. Such a change of control without the payment of a control premium is not in the best interests of stockholders. YZi Labs’ Request...

CALGARY, Alberta, March 13, 2026 (GLOBE NEWSWIRE) — South Bow Corp. (TSX & NYSE: SOBO) (South Bow) filed its 2025 annual disclosure documents on March 13, 2026. South Bow’s audited consolidated financial statements and notes, management’s discussion and analysis, and annual information form as at and for the year ended Dec. 31, 2025, are available on South Bow’s website at www.southbow.com, under South Bow’s SEDAR+ profile at www.sedarplus.ca, and in South Bow’s filings with the U.S. Securities and Exchange Commission at www.sec.gov. About South Bow South Bow safely operates 4,900 kilometres (3,045 miles) of crude oil pipeline infrastructure, connecting Alberta crude oil supplies to U.S. refining markets in Illinois, Oklahoma, and the U.S. Gulf Coast through our unrivalled market position. We take...